Pfizer Inc.

NYSE:PFE   1:45:19 PM EDT
39.44
-0.42 (-1.05%)
Products

U.S. FDA Approves Pfizer's Xeljanz For Treatment Of Active Polyarticular Course Juvenile Idiopathic Arthritis

Published: 09/28/2020 21:30 GMT
Pfizer Inc. (PFE) - U.S. FDA Approves Pfizer’s Xeljanz® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis.
Pfizer Inc - Xeljanz Oral Solution is Anticipated to Be Available by End of Q1 2021.